Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CUE-101

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Cue Biopharma, LG Chem

Drug class:

IL-2 stimulant

Related drugs:

›

No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	CUE-101 Sensitive: B - Late Trials CUE-101 Sensitive : B	CUE-101 Sensitive: B - Late Trials CUE-101 Sensitive : B
HLA-A*02:01 + PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	HLA-A*02:01 + PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + CUE-101 Sensitive: C3 – Early Trials pembrolizumab + CUE-101 Sensitive : C3	pembrolizumab + CUE-101 Sensitive: C3 – Early Trials pembrolizumab + CUE-101 Sensitive : C3
HLA-A*02:01	Squamous Cell Carcinoma of Head and Neck	HLA-A*02:01	Squamous Cell Carcinoma of Head and Neck	CUE-101 Sensitive: C3 – Early Trials CUE-101 Sensitive : C3	CUE-101 Sensitive: C3 – Early Trials CUE-101 Sensitive : C3